XBI241220C80000
- 14.85
- +2.02+15.74%
SPDR S&P Biotech ETF Newsroom
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today
Wolfe's Top 12 Shorted Stocks: FSLR, BE, WBA, and More
Summit Therapeutics Shares Are Trading Higher. The Stock May Be Moving in Sympathy With Neurocrine Biosciences Which Received FDA Approval for CRESNESSITY.
Express News | Live On CNBC, Joe Terranova Announces Sold SPDR Series Trust SPDR S&P Biotech ETF
Another Week, Another Index Record | Lkive Stock
PepGen Stock Craters 35% on FDA Clinical Hold
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential
Tesla To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Monday
Wedbush Reiterates Outperform on Neurocrine Biosciences, Maintains $148 Price Target
Stifel Maintains Hold on Vertex Pharmaceuticals, Raises Price Target to $494
Vertex Pharmaceuticals Analyst Ratings
Neurocrine Biosciences Analyst Ratings
Reported Friday, Neurocrine Biosciences' CRENESSITY Receives FDA Approval, Revolutionizing Treatment For Classic Congenital Adrenal Hyperplasia
SA Asks: How Should Investors Position Portfolios Ahead of Fed Vote?
Weekly Buzz: Tech stocks hit high scores on ominous day
Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
Exact Sciences Analyst Ratings
Market Mixed on Friday the 13th | Livestock
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today